TY - DATA T1 - Supplementary Material for: Possible Inhibitory Effect of Erythropoiesis-Stimulating Agents at the Predialysis Stage on Early-Phase Coronary Events after Hemodialysis Initiation PY - 2016/08/11 AU - Nishimura M AU - Watanabe K. AU - Kitamura Y. AU - Nagashima T. AU - Tokoro T. AU - Takatani T. AU - Sato N. AU - Yamazaki S. AU - Hashimoto T. AU - Kobayashi H. AU - Ono T. UR - https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Possible_Inhibitory_Effect_of_Erythropoiesis-Stimulating_Agents_at_the_Predialysis_Stage_on_Early-Phase_Coronary_Events_after_Hemodialysis_Initiation/3571065 DO - 10.6084/m9.figshare.3571065.v1 L4 - https://ndownloader.figshare.com/files/5648856 KW - •Anemia KW - •Chronic kidney disease KW - •Coronary plaque KW - •Erythropoiesis-stimulating agent KW - •Hemodialysis N2 - Background: We examined whether the use of erythropoiesis-stimulating agents (ESAs) to correct anemia at the predialysis stage could inhibit early-phase coronary events after hemodialysis initiation. Methods: We enrolled 242 patients with chronic kidney disease who had received continued medical treatments and initiated maintenance hemodialysis from 1 September 2000 to 31 December 2014 at Toujinkai Hospital. Patients with a previous history of blood transfusion or any cardiovascular events or interventions were excluded. The coronary events were followed for 1 year after initiation of hemodialysis. Results: Coronary events occurred in 51 of 242 patients: 10 patients had acute coronary syndrome [9 with percutaneous coronary intervention (PCI), 1 without intervention], and 41 had elective coronary revascularization (38 PCI and 3 coronary artery bypass graft). ESA was administered in 118 of 242 patients (48.8%). In stepwise logistic analysis, coronary events were positively associated with nonuse of ESA at the predialysis stage (odds ratio 2.66, p = 0.005) and diabetes mellitus (odds ratio 5.33, p < 0.001). When dividing the patients into 4 subgroups by blood hemoglobin (Hb) level (8.5 g/dl) and the use/nonuse of ESA, coronary event-free survival rates were higher (p = 0.005) in those with Hb ≥8.5 g/dl, ESA+ (86.6%, n = 82) and tended to be higher (p = 0.055) in those with Hb <8.5 g/dl, ESA+ (86.1%, n = 36) than in patients with Hb <8.5 g/dl, ESA- (68.6%, n = 86) in a Kaplan-Meier analysis. Conclusions: The use of ESA to correct anemia at the predialysis stage may inhibit early-phase coronary events after hemodialysis initiation ER -